Sugi Predict

Sugi Predict / Compounds / SCHEMBL2997518

SCHEMBL2997518

SCHEMBL2997518

O=C(O)c1ccc(-c2cc3c(n2-c2cccnc2)CCc2ccccc2-3)cc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SERPINE1 P05121 1/20 0.56
▸ LMNA P02545 4/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ HTT P42858 1/20 0.44
▸ SRD5A2 P31213 2/20 0.44
▸ SRD5A1 P18405 1/20 0.44
▸ MKNK1 Q9BUB5 1/20 0.42
▸ MKNK2 Q9HBH9 1/20 0.42
▸ MAPT P10636 6/20 0.39
▸ TP53 P04637 4/20 0.39
▸ THRB P10828 1/20 0.39
▸ CYP11B2 P19099 2/20 0.38
▸ CYP17A1 P05093 1/20 0.38
▸ CYP19A1 P11511 1/20 0.38
▸ CYP11B1 P15538 1/20 0.38
▸ MARS1 P56192 1/20 0.38
▸ TBXAS1 P24557 2/20 0.37
▸ PDK2 Q15119 1/20 0.37
▸ GRM1 Q13255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2989742 0.90 SERPINE1 (0.54) SERPINE1LMNASRD5A2SRD5A1MAPT
SCHEMBL2987383 0.89 SERPINE1 (0.65) SERPINE1LMNASMN1; SMN2HTTSRD5A2
SCHEMBL2991502 0.86 SERPINE1 (0.57) SERPINE1LMNASMN1; SMN2SRD5A2SRD5A1
SCHEMBL2987677 0.85 SERPINE1 (0.63) SERPINE1LMNASMN1; SMN2HTTSRD5A2
SCHEMBL2988496 0.84 SERPINE1 (0.71) SERPINE1LMNASMN1; SMN2HTTSRD5A2
SCHEMBL2993810 0.82 SERPINE1 (0.60) SERPINE1LMNASMN1; SMN2HTTSRD5A2
SCHEMBL2996651 0.80 SERPINE1 (0.69) SERPINE1LMNASMN1; SMN2HTTSRD5A2
SCHEMBL12091822 0.79 SERPINE1 (0.56) SERPINE1LMNASMN1; SMN2SRD5A2SRD5A1
SCHEMBL12091800 0.78 SERPINE1 (0.68) SERPINE1LMNASMN1; SMN2MAPTTP53
SCHEMBL2995702 0.78 SERPINE1 (0.60) SERPINE1LMNASMN1; SMN2HTTSRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9216966-B2 Compounds for Alzheimer's disease Manfredi, John (US) 2015-12-22 — — US disclosed
US-9216966-B2 Compounds for Alzheimer's disease Manfredi, John (US) 2015-12-22 — — US disclosed
US-9216966-B2 Compounds for Alzheimer's disease Manfredi, John (US) 2015-12-22 — — US disclosed
US-9034871-B2 Compounds for Alzheimer's disease Manfredi, John (US) 2015-05-19 — — US disclosed
US-9034871-B2 Compounds for Alzheimer's disease Manfredi, John (US) 2015-05-19 — — US disclosed
US-9034871-B2 Compounds for Alzheimer's disease Manfredi, John (US) 2015-05-19 — — US disclosed
EP-1809601-B1 COMPOUNDS FOR ALZHEIMER'S DISEASE MANFREDI JOHN (US) 2014-09-10 — — EP disclosed
US-20130261118-A1 COMPOUNDS FOR ALZHEIMER'S DISEASE MANFREDI JOHN (US) 2013-10-03 — — US disclosed
US-20120225873-A1 COMPOUNDS FOR ALZHEIMER'S DISEASE MYREXIS, INC. (US) 2012-09-06 — — US disclosed
US-20120225873-A1 COMPOUNDS FOR ALZHEIMER'S DISEASE MYREXIS, INC. (US) 2012-09-06 — — US disclosed
US-20100184975-A1 COMPOUNDS FOR ALZHEIMBER'S DISEASE MYRIAD PHARMACEUTICALS, INC. (US) 2010-07-22 — — US disclosed
US-7678823-B2 N-phenylindoles; oral dosage forms; side effect reduction Myriad Pharmaceticals, Inc. (US) 2010-03-16 — — US disclosed
US-7678823-B2 N-phenylindoles; oral dosage forms; side effect reduction Myriad Pharmaceticals, Inc. (US) 2010-03-16 — — US disclosed
US-7678823-B2 N-phenylindoles; oral dosage forms; side effect reduction Myriad Pharmaceticals, Inc. (US) 2010-03-16 — — US disclosed
US-20090099179-A1 COMPOUNDS FOR DISEASES AND DISORDERS MYRIAD GENETICS, INCORPORATED (US) 2009-04-16 — — US disclosed
US-20090099179-A1 COMPOUNDS FOR DISEASES AND DISORDERS MYRIAD GENETICS, INCORPORATED (US) 2009-04-16 — — US disclosed
US-20080249135-A1 N-phenylindoles; oral dosage forms; side effect reduction MYRIAD GENETICS, INCORPORATED (US) 2008-10-09 — — US disclosed
US-20080249135-A1 N-phenylindoles; oral dosage forms; side effect reduction MYRIAD GENETICS, INCORPORATED (US) 2008-10-09 — — US disclosed
US-20080249135-A1 N-phenylindoles; oral dosage forms; side effect reduction MYRIAD GENETICS, INCORPORATED (US) 2008-10-09 — — US disclosed
WO-2007115306-A2 COMPOUNDS FOR DISEASES AND DISORDERS MYRIAD GENETICS, INC. (US) 2007-10-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130261118-A1 COMPOUNDS FOR ALZHEIMER'S DISEASE SLC18A2, SLC18A3, NLN SERPINE1 4169/4885LMNA 4285/4885SMN1; SMN2 724/4885
US-20090099179-A1 COMPOUNDS FOR DISEASES AND DISORDERS CLN6, NLN, CLTC SERPINE1 4871/4885LMNA 1125/4885SMN1; SMN2 76/4885
US-20080249135-A1 N-phenylindoles; oral dosage forms; side effect reduction NCL, PSEN2, CCNO SERPINE1 4873/4885LMNA 35/4885SMN1; SMN2 596/4885
US-20100184975-A1 COMPOUNDS FOR ALZHEIMBER'S DISEASE PSEN2, PSEN1, CLN6 SERPINE1 4847/4885LMNA 1067/4885SMN1; SMN2 894/4885
US-20120225873-A1 COMPOUNDS FOR ALZHEIMER'S DISEASE PSEN2, CHAT, PSEN1 SERPINE1 4841/4885LMNA 765/4885SMN1; SMN2 1033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.